<html>
<head>
<title>Clinical Evidence</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="#999999">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="000868" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><font color="#FFFFFF"><a name="Top"></a><img src="../Assets/HFACEtitle.gif" width="430" height="50"></font></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_HFandACE.html"><img src="../Assets/CE1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_HFandACE.html"><img src="../Assets/CE2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_HFandACE.html"><img src="../Assets/CE3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_HFandACE.html"><img src="../Assets/CE4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_HFandACE.html"><img src="../Assets/CE5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_HFandACE.html"><img src="../Assets/CE6.gif" width="121" height="37" border="0"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/CEheader.gif" width="330" height="50" align="baseline"><img src="../Assets/CEheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <font color="#B70000">Last Updated: Janurary, 2002</font> <br>
              <table width="90%" border="0">
                <tr bordercolordark="#ffffff" bordercolorlight="#c2c2c2"> 
                  <td class=heading id=heading><TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
                      <TBODY>
                        <TR> 
                          <TD class=heading id=heading> <SCRIPT src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/0204_i1.0"></SCRIPT> 
                            <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT> 
                            <TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular disorders</SECTION></SPAN><IMG height=10 
            src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR>
                                    <SPAN class=localhead id=localhead><TOPIC>Heart 
                                    failure</TOPIC><IMG height=10 src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/spacer.gif" 
            width=10 align=absMiddle border=0></SPAN></TD>
                                </TR>
                                <TR> 
                                  <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30>Robert McKelvie<IMG height=10 src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/spacer.gif" width=10 
            align=absMiddle border=0></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <H1 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Drug 
                              treatments</H1>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD width="10%" vAlign=top bgcolor="#333333" class=question id=question><B><SPAN 
            class=question-title id=question-title><font color="#FFFFFF">QUESTION</font></SPAN></B></TD>
                                  <TD bgcolor="#CCCCCC" class=question id=question>&nbsp;<B>What 
                                    are the effects of drug treatments in heart 
                                    failure?</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A name=I1> 
                            <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">ACE 
                              inhibitors</H2>
                            <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR class=option id=option> 
                                  <TD 
          width="10%" vAlign=top bgcolor="#000099" class=option id=option style="PADDING-LEFT: 2px"><SPAN class=option-title 
            id=option-title><font color="#FFFFFF">OPTION</font>&nbsp;&nbsp;&nbsp;</SPAN></TD>
                                  <TD 
            width="100%" bgcolor="#CCCCFF" class=option id=option style="PADDING-LEFT: 2px"><B>Angiotensin converting enzyme (ACE) 
                                    inhibitors</B></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            </A> <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD><A name=I1-SUMSTATEMENT><B> 
                                    <P style="MARGIN-LEFT: 3px" align=justify>Two 
                                      systematic reviews and recent RCTs have 
                                      found that ACE inhibitors reduce mortality, 
                                      admission to hospital for heart failure, 
                                      and ischaemic events in people with heart 
                                      failure. Relative benefits are similar in 
                                      different groups of people, but absolute 
                                      benefits are greater in people with severe 
                                      heart failure.</P>
                                    </B></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A 
            name=I1-BENEFITS><B>Benefits: </B></A></FONT>We found two systematic 
                                      reviews of ACE inhibitors versus placebo 
                                      in heart failure. <A 
            href="#references">[20]</A> <A 
            href="#references">[21]</A> The first systematic review (search date 
                                      1994, 32 RCTs, duration 3–42 months, 7105 
                                      people, NYHA class II or worse <A 
            href="../Heart_Failure_and_ACE_CE_content_files092101/Ace%20&%20heart%20glossary%20092101_files/0204_glossary.0" target="_blank">[see 
                                      glossary]<IMG height=15 
            src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/anchor-arrow-12x15-navy.gif" width=12 
            align=absMiddle border=0></A> <A 
            href="#references">[20]</A> found that ACE inhibitors versus placebo 
                                      reduced mortality (611/3870 [16%] with ACE 
                                      inhibitors <EM>v</EM> 709/3235 [22%] with 
                                      placebo; ARR 6%, 95% CI 4% to 8%; OR 0.77, 
                                      95% CI 0.67 to 0.88; NNT 16). Relative reductions 
                                      in mortality were similar in different subgroups 
                                      (stratified by age, sex, cause of heart 
                                      failure, and NYHA class). The second systematic 
                                      overview (search date not stated, 5 RCTs, 
                                      12&nbsp;763 people with left ventricular 
                                      dysfunction or heart failure, mean duration 
                                      35 months) analysed results from individuals 
                                      in long term and large RCTs that compared 
                                      ACE inhibitors versus placebo. <A 
            href="#references">[21]</A> Three RCTs were in people for 1 year after 
                                      myocardial infarction. In these three post 
                                      infarction trials (5966 people), ACE inhibitor 
                                      versus placebo significantly reduced mortality 
                                      (702/2995 [23.4%] <EM>v</EM> 866/2971 [29.1%]; 
                                      OR 0.74, 95% CI 0.66 to 0.83), re-admission 
                                      for heart failure (355/2995 [11.9%] <EM>v</EM> 
                                      460/2971 [15.5%]; OR 0.73, 95% CI 0.63 to 
                                      0.85), and reinfarction (324/2995 [10.8%] 
                                      <EM>v</EM> 391/2971 [13.2%]; OR 0.80, 95% 
                                      CI 0.69 to 0.94]). For all five trials, 
                                      ACE inhibitors versus placebo reduced mortality 
                                      (1467/6391 [23.0%] <EM>v</EM> 1710/6372 
                                      [26.8%]; OR 0.80, 95% CI 0.74 to 0.87), 
                                      reinfarction (571/6391 [8.9%] <EM>v</EM> 
                                      703/6372 [11.0%]; OR 0.79, 95% CI 0.70 to 
                                      0.89), and re-admission for heart failure 
                                      (876/6391 [13.7%] <EM>v</EM> 1202/6372 [18.9%]; 
                                      OR 0.67, 95% CI 0.61 to 0.74). The benefits 
                                      began soon after the start of therapy, persisted 
                                      long term, were independent of age, sex, 
                                      and baseline use of diuretics, aspirin, 
                                      and ß blockers. Although there was a trend 
                                      towards greater relative reduction in mortality 
                                      or re-admission for heart failure in people 
                                      with lower ejection fractions, benefit was 
                                      apparent over the range examined. <B>Other 
                                      ischaemic events:</B> Individual RCTs that 
                                      studied high risk groups found that ACE 
                                      inhibitors significantly reduced some ischaemic 
                                      event rates. One RCT in people with left 
                                      ventricular dysfunction found that, compared 
                                      with placebo, ACE inhibitors reduced myocardial 
                                      infarction (combined fatal or non-fatal 
                                      myocardial infarction: 9.9% <EM>v</EM> 12.3%; 
                                      RRR 23%, 95% CI 2% to 39%), hospital admission 
                                      for angina (15% <EM>v</EM> 19%; RRR 27%, 
                                      95% CI 12% to 40%), and the combined end 
                                      point of cardiac death, non-fatal myocardial 
                                      infarction, or hospital admission for angina 
                                      (43% <EM>v</EM> 51%; RRR 23%, 95% CI 14% 
                                      to 32%). <A 
            href="#references">[9]</A> Effects on hospital re-admissions were 
                                      observed shortly after starting ACE inhibitor 
                                      treatment, although effects on ischaemic 
                                      events were not apparent for at least 6 
                                      months and peaked at 36 months. <B>Dosage:</B> 
                                      We found one large RCT (3164 people with 
                                      <A 
            href="../Heart_Failure_and_ACE_CE_content_files092101/Ace%20&%20heart%20glossary%20092101_files/0204_glossary.0" target="_blank">NYHA 
                                      class II–IV heart failure<IMG height=15 
            src="../Heart_Failure_and_ACE_CE_content_files092101/0204_i1_files/anchor-arrow-12x15-navy.gif" width=12 
            align=absMiddle border=0></A>), which compared low dose lisinopril 
                                      (2.5&nbsp;mg or 5.0&nbsp;mg daily) versus 
                                      high dose lisinopril (32.5&nbsp;mg or 35&nbsp;mg 
                                      daily). <A 
            href="#references">[22]</A> It found no significant difference in 
                                      mortality (717/1596 [44.9%] with low dose 
                                      <EM>v</EM> 666/1568 [42.5%] with high dose; 
                                      ARR 8%, 95% CI not given; hazard ratio 0.92, 
                                      95% CI 0.80 to 1.03; P&nbsp;=&nbsp;0.128), 
                                      but found that high dose lisinopril reduced 
                                      the combined outcome of death or hospital 
                                      admission for any reason (1338 events with 
                                      low dose [83.8%] <EM>v</EM> 1250 events 
                                      with high dose [79.7%]; ARR 12%; hazard 
                                      ratio 0.88, 95% CI 0.82–0.96; P&nbsp;=&nbsp;0.002) 
                                      and reduced admissions for heart failure 
                                      (1576 admissions with low dose <EM>v</EM> 
                                      1199 admissions with high dose; ARR 24%; 
                                      P&nbsp;=&nbsp;0.002). <B>Comparison of different 
                                      ACE inhibitors: </B>The first systematic 
                                      review found similar benefits with different 
                                      ACE inhibitors. <A 
            href="#references">[20]</A> </P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I1-HARMS><B>Harms: 
                                      </B></A></FONT>We found no systematic review. 
                                      The main adverse effects documented in large 
                                      trials were cough, hypotension, hyperkalaemia, 
                                      and renal dysfunction. Compared with placebo, 
                                      ACE inhibitors increased the incidence of 
                                      cough (37% <EM>v</EM> 31%; ARI 7%, 95% CI 
                                      3% to 11%; RRI 23%, 95% CI 11% to 35%; NNH 
                                      14), dizziness or fainting (57% <EM>v</EM> 
                                      50%; ARI 7%, 95% CI 3% to 11%; RRI 14%, 
                                      95% CI 6% to 21%; NNH 14), increased creatinine 
                                      concentrations above 177&nbsp;µmol/litre 
                                      (10.7% <EM>v</EM> 7.7%; ARI 3%, 95% CI 0.6% 
                                      to 6%; RRI 38%, 95% CI 9% to 67%; NNH 34), 
                                      and increased potassium concentrations above 
                                      5.5&nbsp;mmol/litre (ARs 6.4% <EM>v</EM> 
                                      2.5%; ARI 4%, 95% CI 2% to 7%; RRI 156%, 
                                      95% CI 92% to 220%; NNH 26). <A 
            href="#references">[23]</A> Angioedema was not found to be more common 
                                      with ACE inhibitors than placebo (3.8% taking 
                                      enalapril <EM>v</EM> 4.1% taking placebo; 
                                      ARI +0.3%, 95% CI –1.4% to +1.5%). <A 
            href="#references">[23]</A> The trial comparing low and high doses 
                                      of lisinopril found that most adverse effects 
                                      were more common with high dose (no P value 
                                      reported; dizziness: 12% with low dose <EM>v</EM> 
                                      19% with high dose; hypotension: 7% with 
                                      low dose <EM>v</EM> 11% with high dose; 
                                      worsening renal function: 7% with low dose 
                                      <EM>v</EM> 10% with high dose; significant 
                                      change in serum potassium concentration: 
                                      7% with low dose <EM>v</EM> 7% with high 
                                      dose), although there was no difference 
                                      in withdrawal rates between groups (17% 
                                      discontinued with high dose <EM>v</EM> 18% 
                                      with low dose). The trial found that cough 
                                      was less commonly experienced with high 
                                      dose compared with low dose lisinopril (cough: 
                                      13% with low dose <EM>v</EM> 11% with high 
                                      dose).</P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD> <P align=justify><FONT color=#0033cc><A name=I1-COMMENT><B>Comment: 
                                      </B></A></FONT>The relative beneficial effects 
                                      of ACE inhibitors were similar in different 
                                      subgroups of people with heart failure. 
                                      Most RCTs evaluated left ventricular function 
                                      by assessing LVEF, but some studies defined 
                                      heart failure clinically, without measurement 
                                      of left ventricular function in people at 
                                      high risk of developing heart failure (soon 
                                      after myocardial infarction). It is unclear 
                                      whether there are additional benefits from 
                                      adding ACE inhibitor therapy to people with 
                                      heart failure who are already taking antiplatelet 
                                      therapy, and of adding antiplatelet therapy 
                                      to people with heart failure who are already 
                                      taking an ACE inhibitor (see antiplatelet 
                                      agents).</P></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR>
                            <A 
      name=references></A> <TABLE cellSpacing=0 cellPadding=0 border=0>
                              <TBODY>
                                <TR> 
                                  <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
                                  <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD>
                                </TR>
                                <TR> 
                                  <TD class=key-message id=key-message width=90 
            bgColor=#CCCCCC><B>References</B></TD>
                                  <TD width="100%">&nbsp;</TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <BR> <TABLE cellPadding=2 width="100%" align=center>
                              <TBODY>
                                <TR><A class=reference id=reference name=REF9></a> 
                                  <TD class=reference id=reference vAlign=top width=15>9. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Yusuf 
                                    S, Pepine CJ, Garces C, et al. Effect of enalapril 
                                    on myocardial infarction and unstable angina 
                                    in patients with low ejection fractions. <EM>Lancet</EM> 
                                    1992;340:1173–1178. </TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF20></a> 
                                  <TD class=reference id=reference vAlign=top width=15>20. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Garg 
                                    R, Yusuf S, for the Collaborative Group on 
                                    ACE Inhibitor Trials. Overview of randomized 
                                    trials of angiotensin-converting enzyme inhibitors 
                                    on mortality and morbidity in patients with 
                                    heart failure. <EM>JAMA</EM> 1995;273:1450–1456. 
                                    Search date 1994; primary sources Medline; 
                                    correspondence with investigators and pharmaceutical 
                                    firms.</TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF21></a> 
                                  <TD class=reference id=reference vAlign=top width=15>21. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Flather 
                                    M, Yusuf S, Kober L, et al, for the ACE-Inhibitor 
                                    Myocardial Infarction Collaborative Group. 
                                    Long-term ACE-inhibitor therapy in patients 
                                    with heart failure or left-ventricular dysfunction: 
                                    a systematic overview of data from individual 
                                    patients. <EM>Lancet</EM> 2000;355:1575–1581. 
                                    Search date not stated; primary sources Medline; 
                                    Ovid; and hand searches of reference lists 
                                    and personal contact with researchers, colleagues 
                                    and principal investigators of the trials 
                                    identified.</TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF22></a> 
                                  <TD class=reference id=reference vAlign=top width=15>22. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">Packer 
                                    M, Poole-Wilson PA, Armstrong PW, et al, on 
                                    behalf of the ATLAS Study Group. Comparative 
                                    effects of low and high doses of the angiotensin-converting 
                                    enzyme inhibitor, lisinopril, on morbidity 
                                    and mortality in chronic heart failure. <EM>Circulation</EM> 
                                    1999;100:2312–2318.</TD>
                                </TR>
                                <TR><A class=reference id=reference name=REF23></a> 
                                  <TD class=reference id=reference vAlign=top width=15>23. 
                                  </TD>
                                  <TD class=reference id=reference vAlign=top width="100%">SOLVD 
                                    Investigators. Effect of enalapril on survival 
                                    in patients with reduced left ventricular 
                                    ejection fractions and congestive heart failure. 
                                    <EM>N Engl J Med</EM> 1991;325:293–302. </TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <TABLE width="100%" border=0>
                              <TBODY>
                                <TR> 
                                  <TD vAlign=bottom width="50%"> 
                                  
                              <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="../Assets/ce-pagebrand.jpg" 
            border=0 width="89" height="44"></TD>
                                </TR>
                                <TR> 
                                  <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 2001</SPAN></TD>
                                  <TD align=right width="50%"><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=1106&amp;t=document-frame.htm&amp;p=copyright.html&amp;2.0"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></A></TD>
                                </TR>
                              </TBODY>
                            </TABLE>
                            <SCRIPT language=JavaScript>
			var purl = "0204.PDF"; 
</SCRIPT> </TD>
                        </TR>
                      </TBODY>
                    </TABLE> </td>
                </tr>
                <tr> 
                  <td>
                    <div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div>
                  </td>
                </tr>
              </table>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="#3333FF"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>
